{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:28Z","timestamp":1790298208253,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["TMU112-AE1-B04"],"award-info":[{"award-number":["TMU112-AE1-B04"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022600","name":"Wan Fang Hospital","doi-asserted-by":"publisher","award":["113-wf-eva-16"],"award-info":[{"award-number":["113-wf-eva-16"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic efficacy of topical RBM for dry eye disease (DED) treatment remains inconclusive. Accordingly, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the effectiveness of RBM for DED treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched the PubMed, Embase, and Cochrane Library databases for eligible RCTs. The primary outcome was posttreatment changes in tear breakup time (TBUT). We also assessed changes in the values of Schirmer\u2019s test (Sch), corneal fluorescein staining scores, and DED-related symptom scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We retrieved 12 RCTs with 1368 eyes published during 2012\u20132023. The results demonstrated that compared with artificial tears, 2% RBM significantly increased the TBUT [standard mean difference (SMD)\u2009=\u20091.42, 95% confidence interval (CI)\u2009=\u20090.20 to 2.64]. Moreover, 2% RBM led to more significant improvements in overall DED-related symptom scores than did artificial tears (SMD\u2009= \u2212\u20091.61, 95% CI\u2009= \u2212\u20092.61 to\u2009\u2212\u20090.61). The differences in the adverse events between the 2% RBM and artificial tears groups were nonsignificant (SMD\u2009=\u20091.23, 95% CI\u2009=\u20090.62 to 2.44).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Topical RBM ophthalmic suspension is a safe and effective treatment for DED patients. Compared to artificial tears, 2% RBM improved TBUT and subjective symptoms of DED. It may be considered as the first-line treatment option for short- TBUT dry eye patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12886-025-04146-0","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:56:55Z","timestamp":1748329015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of rebamipide compared to artificial tears for the treatment of dry eye: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Ching-Wen","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Wai","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-2800","authenticated-orcid":false,"given":"I-Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"4146_CR1","doi-asserted-by":"publisher","unstructured":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007(2):75\u201392. https:\/\/doi.org\/10.1016\/s1542-0124(12)70081-2. PMID: 17508116.","DOI":"10.1016\/s1542-0124(12)70081-2"},{"key":"4146_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1442-9071.2003.00634.x","volume":"31","author":"EM Chia","year":"2003","unstructured":"Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2003;31:229\u201332.","journal-title":"Clin Exp Ophthalmol"},{"key":"4146_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","volume":"136","author":"DA Schaumberg","year":"2003","unstructured":"Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318\u201326.","journal-title":"Am J Ophthalmol"},{"key":"4146_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334\u201365.","journal-title":"Ocul Surf"},{"key":"4146_CR5","first-page":"71","volume":"112","author":"EM Messmer","year":"2015","unstructured":"Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71\u201382.","journal-title":"Dtsch Arztebl Int"},{"key":"4146_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","volume":"1","author":"M Uchino","year":"2013","unstructured":"Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2013;1:51\u20137.","journal-title":"Curr Ophthalmol Rep"},{"key":"4146_CR7","doi-asserted-by":"publisher","first-page":"e0242617","DOI":"10.1371\/journal.pone.0242617","volume":"15","author":"J Shoji","year":"2020","unstructured":"Shoji J, Inada N, Tomioka A, et al. Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sj\u00f6gren\u2019s syndrome-associated dry eyes. PLoS ONE. 2020;15:e0242617.","journal-title":"PLoS ONE"},{"key":"4146_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/jop.2011.0142","volume":"28","author":"Y Takeji","year":"2012","unstructured":"Takeji Y, Urashima H, Aoki A, et al. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28:259\u201363.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4146_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exer.2016.10.007","volume":"153","author":"Y Uchino","year":"2016","unstructured":"Uchino Y, Woodward AM, Arg\u00fceso P. Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cells. Exp Eye Res. 2016;153:1\u20137.","journal-title":"Exp Eye Res"},{"key":"4146_CR10","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1167\/iovs.12-11294","volume":"54","author":"K Kimura","year":"2013","unstructured":"Kimura K, Morita Y, Orita T, et al. Protection of human corneal epithelial cells from TNF-\u03b1-induced disruption of barrier function by rebamipide. Invest Ophthalmol Vis Sci. 2013;54:2572\u2013760.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4146_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/2045-7022-4-40","volume":"4","author":"M Ueta","year":"2014","unstructured":"Ueta M, Shoji J, Sotozono C, et al. Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops. Clin Transl Allergy. 2014;4:40.","journal-title":"Clin Transl Allergy"},{"key":"4146_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12886-023-03004-1","volume":"23","author":"Y Eom","year":"2023","unstructured":"Eom Y, Chung SH, Chung T, et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023;23:343.","journal-title":"BMC Ophthalmol"},{"key":"4146_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/ICO.0000000000000456","volume":"34","author":"A Igarashi","year":"2015","unstructured":"Igarashi A, Kamiya K, Kobashi H, et al. Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery. Cornea. 2015;34:895\u2013900.","journal-title":"Cornea"},{"key":"4146_CR14","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","volume":"119","author":"S Kinoshita","year":"2012","unstructured":"Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology. 2012;119:2471\u20138.","journal-title":"Ophthalmology"},{"key":"4146_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","volume":"120","author":"S Kinoshita","year":"2013","unstructured":"Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013;120:1158\u201365.","journal-title":"Ophthalmology"},{"key":"4146_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/jop.2016.0096","volume":"33","author":"H Kobashi","year":"2017","unstructured":"Kobashi H, Kamiya K, Shimizu K. Randomized comparison between rebamipide ophthalmic suspension and diquafosol ophthalmic solution for dry eye after penetrating keratoplasty. J Ocul Pharmacol Ther. 2017;33:13\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4146_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","volume":"32","author":"S Koh","year":"2013","unstructured":"Koh S, Inoue Y, Sugmimoto T, et al. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32:1219\u201323.","journal-title":"Cornea"},{"key":"4146_CR18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40123-022-00523-w","volume":"11","author":"T Teshigawara","year":"2022","unstructured":"Teshigawara T, Meguro A, Mizuki N. Impact of perioperative dry eye treatment with rebamipide versus artificial tears on visual outcomes after cataract surgery in Japanese population. Ophthalmol Ther. 2022;11:1479\u201391.","journal-title":"Ophthalmol Ther"},{"key":"4146_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12886-015-0040-0","volume":"15","author":"K Ueda","year":"2015","unstructured":"Ueda K, Matsumiya W, Otsuka K, et al. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol. 2015;15:58.","journal-title":"BMC Ophthalmol"},{"key":"4146_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"4146_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/BF02332860","volume":"235","author":"Y Danjo","year":"1997","unstructured":"Danjo Y. Diagnostic usefulness and cutoff value of Schirmer\u2019s I test in the Japanese diagnostic criteria of dry eye. Graefes Arch Clin Exp Ophthalmol. 1997;235:761\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4146_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00003226-199801000-00007","volume":"17","author":"SC Pflugfelder","year":"1998","unstructured":"Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998;17:38\u201356.","journal-title":"Cornea"},{"key":"4146_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtos.2019.01.004","volume":"17","author":"C Begley","year":"2019","unstructured":"Begley C, Caffery B, Chalmers R, et al. Review and analysis of grading scales for ocular surface staining. Ocul Surf. 2019;17:208\u201320.","journal-title":"Ocul Surf"},{"key":"4146_CR24","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0. The Cochrane Collaboration.\u00a02011."},{"key":"4146_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1\u201334.","journal-title":"J Clin Epidemiol"},{"key":"4146_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"4146_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/jcor.jcor_50_19","volume":"9","author":"PV Gandhi","year":"2021","unstructured":"Gandhi PV, Telang O, Morepati V. Comparing the efficacy of 2% topical rebamipide and 0.1% topical sodium hyaluronate with or without 0.05% topical cyclosporine in patients with dry eye disease. J Clin Ophthalmol Res. 2021;9:55\u20138.","journal-title":"J Clin Ophthalmol Res"},{"key":"4146_CR28","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.4103\/IJO.IJO_2586_22","volume":"71","author":"K Jain","year":"2023","unstructured":"Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian J Ophthalmol. 2023;71:1598\u2013602.","journal-title":"Indian J Ophthalmol"},{"key":"4146_CR29","first-page":"526","volume":"4","author":"DB Patel","year":"2018","unstructured":"Patel DB, Menon P, Rathod A, et al. A comparative study of rebamipide 2% and carboxy methylcellulose (CMC) 0.5% eye drop in patients with dry eyes: a randomized, hospital-based study. Indian J Clin Exp Ophthalmol. 2018;4:526\u20139.","journal-title":"Indian J Clin Exp Ophthalmol"},{"key":"4146_CR30","doi-asserted-by":"publisher","unstructured":"Rajguru SK, Rajpurohit U. To evaluate the effect of topical 2% rebamipide ophthalmic suspension in patients with dry eye disease. Int J Med Biomed Stud. 2021;5(8).\u00a0https:\/\/doi.org\/10.32553\/ijmbs.v5i8.2067.","DOI":"10.32553\/ijmbs.v5i8.2067"},{"key":"4146_CR31","first-page":"84","volume":"23","author":"AK Sharma","year":"2021","unstructured":"Sharma AK, Sharma S, Sharma HR. Comparison of 2% rebamipide and 0.1% sodium hyaluronate in the treatment of dry eye. JK Sci. 2021;23:84\u20138.","journal-title":"JK Sci"},{"key":"4146_CR32","doi-asserted-by":"publisher","first-page":"15210","DOI":"10.1038\/s41598-017-13121-9","volume":"7","author":"J Shimazaki","year":"2017","unstructured":"Shimazaki J, Seika D, Saga M, et al. A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers. Sci Rep. 2017;7:15210.","journal-title":"Sci Rep"},{"key":"4146_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40123-021-00368-9","volume":"10","author":"T Teshigawara","year":"2021","unstructured":"Teshigawara T, Meguro A, Mizuki N. Effects of Rebamipide on differences in power and axis of corneal astigmatism between two intra-patient keratometric measurements in dry eyes. Ophthalmol Ther. 2021;10:891\u2013904.","journal-title":"Ophthalmol Ther"},{"key":"4146_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1272\/jnms.82.229","volume":"82","author":"T Igarashi","year":"2015","unstructured":"Igarashi T, Fujita M, Yamada Y, et al. Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide. J Nippon Med Sch. 2015;82:229\u201336.","journal-title":"J Nippon Med Sch"},{"key":"4146_CR35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2147\/OPTH.S256351","volume":"14","author":"G Jerkins","year":"2020","unstructured":"Jerkins G, Greiner JV, Tong L, et al. A comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease. Clin Ophthalmol. 2020;14:1665\u201373.","journal-title":"Clin Ophthalmol"},{"key":"4146_CR36","doi-asserted-by":"publisher","first-page":"e000697","DOI":"10.1136\/bmjophth-2020-000697","volume":"6","author":"M Kim","year":"2020","unstructured":"Kim M, Lee Y, Mehra D, et al. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2020;6:e000697.","journal-title":"BMJ Open Ophthalmol"},{"key":"4146_CR37","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1038\/s41598-022-11035-9","volume":"12","author":"M Ayaki","year":"2022","unstructured":"Ayaki M, Negishi K. Decrease of tear break-up time at Japanese eye clinics during five consecutive years. Sci Rep. 2022;12:6848.","journal-title":"Sci Rep"},{"issue":"2","key":"4146_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0161-6420(95)31024-X","volume":"102","author":"I Toda","year":"1995","unstructured":"Toda I, Shimazaki J, Tsubota K. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis. Ophthalmology. 1995;102(2):302\u201329.","journal-title":"Ophthalmology"},{"key":"4146_CR39","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.3390\/pharmaceutics15112591","volume":"15","author":"A Kawahara","year":"2023","unstructured":"Kawahara A. Treatment of Dry Eye Disease (DED) in Asia: strategies for short tear film breakup time-type DED. Pharmaceutics. 2023;15:2591.","journal-title":"Pharmaceutics"},{"key":"4146_CR40","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/ICL.0000000000000643","volume":"46","author":"K Tsubota","year":"2020","unstructured":"Tsubota K, Yokoi N, Watanabe H, et al. A new perspective on dry eye classification: proposal by the Asia Dry Eye Society. Eye Contact Lens. 2020;46:S2\u201313.","journal-title":"Eye Contact Lens"},{"key":"4146_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2017.05.022","volume":"180","author":"N Yokoi","year":"2017","unstructured":"Yokoi N, Georgiev GA, Kato H, et al. Classification of fluorescein breakup patterns: a novel method of differential diagnosis for dry eye. Am J Ophthalmol. 2017;180:72\u201385.","journal-title":"Am J Ophthalmol"},{"key":"4146_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.18231\/j.ijceo.2019.110","volume":"5","author":"DN Prakash","year":"2019","unstructured":"Prakash DN, Sajjan S, Satish K, Raghavendra R, et al. Role of 2% rebamipide ophthalmic suspension in the management of dry eye disease. Indian J Clin Exp Ophthalmo. 2019;5:461\u20135.","journal-title":"Indian J Clin Exp Ophthalmo"},{"key":"4146_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ojo.OJO_29_2017","volume":"11","author":"S Shrivastava","year":"2018","unstructured":"Shrivastava S, Patkar P, Ramakrishnan R, et al. Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes. Oman J Ophthalmol. 2018;11:207\u201312.","journal-title":"Oman J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04146-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:01:52Z","timestamp":1748372512000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04146-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4146"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04146-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is not required as our study will not include confidential participant data and intervention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}